Latest filingSep 09, 2026Most recent Form 4
RAPP
Rapport Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$386M7 sells
Net open-market-$386M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period7transactions
- S · Open-market sells · dominant7 · 100%
Activity by reported role
A joint filing can contribute to multiple roles7transactions
- CDO · dominant4 · 57%
- Chief executive officer3 · 43%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeYeleswaram KrishnaswamyCommon Stock · Direct
212,063Aug 25, 2026
Ceesay AbrahamCommon Stock · Direct
460,046Sep 08, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 09 → Sep 09
LessMore
Top insiders
By absolute net value across the selected period- CA-$374.5k
- YK-$20.2k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
RAPP transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| RAPP | Ceesay Abraham | CEO | sale10b5-1 | 1.06k | -$4.91M | S | — | 0.0% | 09/09 | 09/08 |
| RAPP | Ceesay Abraham | CEO | sale10b5-1 | 7.14k | -$32.5M | S | — | 0.0% | 09/09 | 09/08 |
| RAPP | Yeleswaram Krishnaswamy | CDO | sale10b5-1 | 404 | -$2.01M | S | +1.4% | 08/20 | 08/19 |
Rapport Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Rapport Therapeutics, Inc.?
Ceesay Abraham, Yeleswaram Krishnaswamy.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Ceesay Abraham reported a sale on Sep 08, 2026 valued at $4.91M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $3,864,197.44. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.